Wockhardt reports net loss of Rs 237 crore in Q4FY23
Wockhardt had agreed to pay $36 million and interest over nine installments between 2022 and 2025 to the State of Texas in a drug pricing case that alleged that it was overcharged for drugs supplied to the Texas Medicaid Program.The company recorded a revenue of Rs.710 crore in Q4FY23 compared to Rs.666 crore in Q4FY22, registering a growth of 7%.
